IBDEI0Q8 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11785,0)
;;=N08.^^46^573^21
;;^UTILITY(U,$J,358.3,11785,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11785,1,3,0)
;;=3^Glomerular disorders in diseases classified elsewhere
;;^UTILITY(U,$J,358.3,11785,1,4,0)
;;=4^N08.
;;^UTILITY(U,$J,358.3,11785,2)
;;=^5015569
;;^UTILITY(U,$J,358.3,11786,0)
;;=C90.00^^46^574^10
;;^UTILITY(U,$J,358.3,11786,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11786,1,3,0)
;;=3^Multiple myeloma not having achieved remission
;;^UTILITY(U,$J,358.3,11786,1,4,0)
;;=4^C90.00
;;^UTILITY(U,$J,358.3,11786,2)
;;=^5001752
;;^UTILITY(U,$J,358.3,11787,0)
;;=C90.01^^46^574^9
;;^UTILITY(U,$J,358.3,11787,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11787,1,3,0)
;;=3^Multiple myeloma in remission
;;^UTILITY(U,$J,358.3,11787,1,4,0)
;;=4^C90.01
;;^UTILITY(U,$J,358.3,11787,2)
;;=^267515
;;^UTILITY(U,$J,358.3,11788,0)
;;=C90.02^^46^574^8
;;^UTILITY(U,$J,358.3,11788,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11788,1,3,0)
;;=3^Multiple myeloma in relapse
;;^UTILITY(U,$J,358.3,11788,1,4,0)
;;=4^C90.02
;;^UTILITY(U,$J,358.3,11788,2)
;;=^5001753
;;^UTILITY(U,$J,358.3,11789,0)
;;=E11.29^^46^574^22
;;^UTILITY(U,$J,358.3,11789,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11789,1,3,0)
;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
;;^UTILITY(U,$J,358.3,11789,1,4,0)
;;=4^E11.29
;;^UTILITY(U,$J,358.3,11789,2)
;;=^5002631
;;^UTILITY(U,$J,358.3,11790,0)
;;=E11.21^^46^574^21
;;^UTILITY(U,$J,358.3,11790,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11790,1,3,0)
;;=3^Type 2 DM w/ Diabetic nephropathy
;;^UTILITY(U,$J,358.3,11790,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,11790,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,11791,0)
;;=E11.22^^46^574^20
;;^UTILITY(U,$J,358.3,11791,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11791,1,3,0)
;;=3^Type 2 DM w/ Diabetic CKD
;;^UTILITY(U,$J,358.3,11791,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,11791,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,11792,0)
;;=E10.29^^46^574^19
;;^UTILITY(U,$J,358.3,11792,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11792,1,3,0)
;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
;;^UTILITY(U,$J,358.3,11792,1,4,0)
;;=4^E10.29
;;^UTILITY(U,$J,358.3,11792,2)
;;=^5002591
;;^UTILITY(U,$J,358.3,11793,0)
;;=E10.21^^46^574^18
;;^UTILITY(U,$J,358.3,11793,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11793,1,3,0)
;;=3^Type 1 DM w/ Diabetic Nephropathy
;;^UTILITY(U,$J,358.3,11793,1,4,0)
;;=4^E10.21
;;^UTILITY(U,$J,358.3,11793,2)
;;=^5002589
;;^UTILITY(U,$J,358.3,11794,0)
;;=E10.22^^46^574^17
;;^UTILITY(U,$J,358.3,11794,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11794,1,3,0)
;;=3^Type 1 DM w/ Diabetic CKD
;;^UTILITY(U,$J,358.3,11794,1,4,0)
;;=4^E10.22
;;^UTILITY(U,$J,358.3,11794,2)
;;=^5002590
;;^UTILITY(U,$J,358.3,11795,0)
;;=D59.3^^46^574^3
;;^UTILITY(U,$J,358.3,11795,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11795,1,3,0)
;;=3^Hemolytic-uremic syndrome
;;^UTILITY(U,$J,358.3,11795,1,4,0)
;;=4^D59.3
;;^UTILITY(U,$J,358.3,11795,2)
;;=^55823
;;^UTILITY(U,$J,358.3,11796,0)
;;=D69.0^^46^574^4
;;^UTILITY(U,$J,358.3,11796,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11796,1,3,0)
;;=3^Henoch-Schoeniein Purpura
;;^UTILITY(U,$J,358.3,11796,1,4,0)
;;=4^D69.0
;;^UTILITY(U,$J,358.3,11796,2)
;;=^5002365
;;^UTILITY(U,$J,358.3,11797,0)
;;=M30.0^^46^574^12
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Q8 3745 printed Oct 16, 2024@17:54:28 Page 2
IBDEI0Q8 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11785,0)
+2 ;;=N08.^^46^573^21
+3 ;;^UTILITY(U,$J,358.3,11785,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,11785,1,3,0)
+6 ;;=3^Glomerular disorders in diseases classified elsewhere
+7 ;;^UTILITY(U,$J,358.3,11785,1,4,0)
+8 ;;=4^N08.
+9 ;;^UTILITY(U,$J,358.3,11785,2)
+10 ;;=^5015569
+11 ;;^UTILITY(U,$J,358.3,11786,0)
+12 ;;=C90.00^^46^574^10
+13 ;;^UTILITY(U,$J,358.3,11786,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,11786,1,3,0)
+16 ;;=3^Multiple myeloma not having achieved remission
+17 ;;^UTILITY(U,$J,358.3,11786,1,4,0)
+18 ;;=4^C90.00
+19 ;;^UTILITY(U,$J,358.3,11786,2)
+20 ;;=^5001752
+21 ;;^UTILITY(U,$J,358.3,11787,0)
+22 ;;=C90.01^^46^574^9
+23 ;;^UTILITY(U,$J,358.3,11787,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,11787,1,3,0)
+26 ;;=3^Multiple myeloma in remission
+27 ;;^UTILITY(U,$J,358.3,11787,1,4,0)
+28 ;;=4^C90.01
+29 ;;^UTILITY(U,$J,358.3,11787,2)
+30 ;;=^267515
+31 ;;^UTILITY(U,$J,358.3,11788,0)
+32 ;;=C90.02^^46^574^8
+33 ;;^UTILITY(U,$J,358.3,11788,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,11788,1,3,0)
+36 ;;=3^Multiple myeloma in relapse
+37 ;;^UTILITY(U,$J,358.3,11788,1,4,0)
+38 ;;=4^C90.02
+39 ;;^UTILITY(U,$J,358.3,11788,2)
+40 ;;=^5001753
+41 ;;^UTILITY(U,$J,358.3,11789,0)
+42 ;;=E11.29^^46^574^22
+43 ;;^UTILITY(U,$J,358.3,11789,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,11789,1,3,0)
+46 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
+47 ;;^UTILITY(U,$J,358.3,11789,1,4,0)
+48 ;;=4^E11.29
+49 ;;^UTILITY(U,$J,358.3,11789,2)
+50 ;;=^5002631
+51 ;;^UTILITY(U,$J,358.3,11790,0)
+52 ;;=E11.21^^46^574^21
+53 ;;^UTILITY(U,$J,358.3,11790,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,11790,1,3,0)
+56 ;;=3^Type 2 DM w/ Diabetic nephropathy
+57 ;;^UTILITY(U,$J,358.3,11790,1,4,0)
+58 ;;=4^E11.21
+59 ;;^UTILITY(U,$J,358.3,11790,2)
+60 ;;=^5002629
+61 ;;^UTILITY(U,$J,358.3,11791,0)
+62 ;;=E11.22^^46^574^20
+63 ;;^UTILITY(U,$J,358.3,11791,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,11791,1,3,0)
+66 ;;=3^Type 2 DM w/ Diabetic CKD
+67 ;;^UTILITY(U,$J,358.3,11791,1,4,0)
+68 ;;=4^E11.22
+69 ;;^UTILITY(U,$J,358.3,11791,2)
+70 ;;=^5002630
+71 ;;^UTILITY(U,$J,358.3,11792,0)
+72 ;;=E10.29^^46^574^19
+73 ;;^UTILITY(U,$J,358.3,11792,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,11792,1,3,0)
+76 ;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
+77 ;;^UTILITY(U,$J,358.3,11792,1,4,0)
+78 ;;=4^E10.29
+79 ;;^UTILITY(U,$J,358.3,11792,2)
+80 ;;=^5002591
+81 ;;^UTILITY(U,$J,358.3,11793,0)
+82 ;;=E10.21^^46^574^18
+83 ;;^UTILITY(U,$J,358.3,11793,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,11793,1,3,0)
+86 ;;=3^Type 1 DM w/ Diabetic Nephropathy
+87 ;;^UTILITY(U,$J,358.3,11793,1,4,0)
+88 ;;=4^E10.21
+89 ;;^UTILITY(U,$J,358.3,11793,2)
+90 ;;=^5002589
+91 ;;^UTILITY(U,$J,358.3,11794,0)
+92 ;;=E10.22^^46^574^17
+93 ;;^UTILITY(U,$J,358.3,11794,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,11794,1,3,0)
+96 ;;=3^Type 1 DM w/ Diabetic CKD
+97 ;;^UTILITY(U,$J,358.3,11794,1,4,0)
+98 ;;=4^E10.22
+99 ;;^UTILITY(U,$J,358.3,11794,2)
+100 ;;=^5002590
+101 ;;^UTILITY(U,$J,358.3,11795,0)
+102 ;;=D59.3^^46^574^3
+103 ;;^UTILITY(U,$J,358.3,11795,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,11795,1,3,0)
+106 ;;=3^Hemolytic-uremic syndrome
+107 ;;^UTILITY(U,$J,358.3,11795,1,4,0)
+108 ;;=4^D59.3
+109 ;;^UTILITY(U,$J,358.3,11795,2)
+110 ;;=^55823
+111 ;;^UTILITY(U,$J,358.3,11796,0)
+112 ;;=D69.0^^46^574^4
+113 ;;^UTILITY(U,$J,358.3,11796,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,11796,1,3,0)
+116 ;;=3^Henoch-Schoeniein Purpura
+117 ;;^UTILITY(U,$J,358.3,11796,1,4,0)
+118 ;;=4^D69.0
+119 ;;^UTILITY(U,$J,358.3,11796,2)
+120 ;;=^5002365
+121 ;;^UTILITY(U,$J,358.3,11797,0)
+122 ;;=M30.0^^46^574^12
